Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization

Gianluigi Savarese, MD, PhD; Lars H. Lund, MD, PhD; Ulf Dahlström, MD, PhD; Anna Strömberg, PhD

Background—Follow-up in a nurse-led heart failure (HF) clinic is recommended in HF guidelines, but its association with outcomes remains controversial, with previous studies including few and highly selected patients. Thus, large analyses of “real-world” samples are needed. Aims were to assess: (1) independent predictors of and (2) prognosis associated with planned referral to nurse-led HF clinics.

Methods and Results—We analyzed data from the SwedeHF (Swedish HF Registry) using multivariable logistic regressions to identify independent predictors of planned referral to a nurse-led HF clinic and multivariable Cox regressions to test associations between planned referral and outcomes (all-cause death, HF hospitalization, and their composite). Of 40 992 patients, 39% were planned to be referred to a follow-up in a nurse-led HF clinic. Independent characteristics associated with planned referral were shorter duration of HF, clinical markers of more-severe HF, such as lower ejection fraction, higher New York Heart Association class and N-terminal pro-B-type natriuretic peptide, and lower blood pressure, as well as cohabitating versus living alone, male sex, fewer comorbidities, and more use of HF treatments. After adjustments, planned referral to a nurse-led HF clinic was associated with reduced mortality and mortality/HF hospitalization, but not HF hospitalization alone.

Conclusions—In this nation-wide registry, 39% of our identified HF cohort was planned to be referred to a nurse-led HF clinic. Planned referral reflected more-severe HF, but also sex- and family-related factors, and it was independently associated with lower risk of death, but not of HF hospitalization. (J Am Heart Assoc. 2019;8:e011737. DOI: 10.1161/JAHA.118.011737.)

Key Words: follow-up • heart failure • hospitalization • nurse-led clinic • registry • survival

Heart failure (HF) is a common condition with 2% prevalence in the general population and >10% among people aged >70 years.1,2 Because of aging of the population and life-prolonging cardiovascular treatments and care, prevalence of HF and HF-related hospital admissions and, consequently, overall costs are increasing.1–4 Additionally, despite the improvements in treatments and organization of care, prognosis still remains poor, with postdischarge mortality rates up to 15% and 20% to 30% readmission rates within the first 30 days after discharge.5 It is of greatest importance to improve the organization of care to provide evidence-based care of high quality in the most cost-effective way.

Sweden has a long tradition of providing follow-up in nurse-led HF clinics, which is relatively uniform across the country. Clinics can be both primary care6 and hospital based,7 but have similar structure and content. Nurses provide education on self-care and psychosocial support to patients and their family, and they independently perform physical examination and assess mental well-being. They can uptitrate medications to optimized doses and occasionally prescribe new treatments with co-signatures by the responsible physician. The number of follow-up visits is individualized for each patient based on symptoms, disease severity, and time needed to reach optimized treatment and sufficient self-care. Most patient come to the clinic for a series of visits, and more-unstable patients are followed over a longer period of time.5,7 Nurses have a specialized education based on content of the curriculum for HF nurses developed by the European Society of Cardiology HF Association.8 Although HF nurses do not make medical decisions or admit to the hospital, they work in close physical proximity to physicians who can assess patients and make decisions, if needed.
Clinical Perspective

What Is New?

- Previous analyses assessing prognosis associated with referral to nurse-led heart failure (HF) clinics included few and highly selected patients, and large analyses of "real-world" populations are missing.
- In our analysis of the Swedish HF registry, 39% of this HF cohort was planned to be referred to a nurse-led HF clinic, and those patients who were planned for referral had more-severe HF, higher use of HF treatments, and less comorbidities at referral.
- Planned referral was independently associated with lower risk of death, but not of HF hospitalization.

What Are Clinical Implications?

- Referral to nurse-led HF clinics is associated with improved survival.
- Closer monitoring may foster earlier identification of patients with worsening status, who may be subsequently hospitalized preventing death.

Previous individual studies and meta-analyses showed improved outcomes in patients referred to nurse-led HF clinics.⁹ According to the 2013 American College of Cardiology Foundation/American Heart Association and the 2016 European Society of Cardiology guidelines on HF, follow-up in a nurse-led HF clinic, as part of multidisciplinary management and monitoring of patients with HF, has recommendation and level of evidence of IB and IA, respectively.²,⁴ However, previous analyses assessing prognosis associated with referral to nurse-led HF clinics included few and highly selected patients,⁹–¹¹ and large analyses of "real-world" populations are needed.

Aims of this analysis were to assess: (1) independent predictors of and (2) prognosis associated with planned referral to a nurse-led HF clinic in a large and unselected cohort of HF patients.

Methods

Study Protocol and Setting

The data that support the findings of this study are available from the corresponding author, provided that data sharing is permitted by European Union General Data Protection Regulation regulations and appropriate ethics committees.

The SwedeHF (Swedish Heart Failure Registry) (www.swedeHF.se) has been previously described.¹² The only inclusion criterion is clinician-diagnosed HF. Approximately 80 variables are recorded at discharge from hospital or after outpatient clinic visit on a web-based case report form and entered into a database managed by the Uppsala Clinical Research Center (www.ucr.uu.se).

The Swedish Board of Health and Welfare (www.socialstyrelsen.se) administers the Population Registry and the Patient Registry. The Population Registry provided date of death. From the Patient Registry, we obtained additional baseline comorbidities and HF hospitalization outcome, defined according to International Classification of Diseases, Tenth Revision (ICD-10) codes in the first position.

Statistics Sweden (www.scb.se) provided socioeconomic characteristics. All Swedish citizens have unique personal identification numbers that enable linking of disease-specific health registries and governmental health and statistical registries.

Establishment of the HF registry and this analysis with linking of the above registries were approved by a multisite ethics committee. Individual patient consent is not required, but patients in Sweden are informed of entry into national registries and allowed to opt out.

Patients

In the current study, patients were selected if they were registered in the SwedeHF as outpatient or discharged alive from the hospital between May 11, 2000 (the start of the registry) and December 31, 2012, they had no missing data for planned follow-up in nurse-led HF clinic and ejection fraction (EF), and had follow-up ≥0 days (ie, follow-up=0 days may be attributed to in-hospital death during the hospitalization that prompted the registration in the SwedeHF; follow-up <0 may be explained by the registration in the SwedeHF after death). When a patient reported more than 1 registration, the first was selected. The index date was defined as the date of the outpatient clinic visit for HF or hospital discharge. End of follow-up was December 31, 2012.

Statistical Analysis

Baseline characteristics

Baseline characteristics were compared in patients planned to be versus not be referred to follow-up in a nurse-led HF clinic by t test or Wilcoxon–Mann–Whitney tests for continuous variables and by chi-squared for categorical variables. Missing data were handled by chained equations multiple imputation (10 data sets generated) in multivariable models. Variables included in the multiple imputation models are labeled with an asterisk (“*”) in Table.

Determinants of planned follow-up in a nurse-led HF clinic

Multivariable logistic regressions, using planned follow-up in a nurse-led HF clinic as a dependent variable and 39 variables
Table. Baseline Characteristics

| Variables                                      | Planned Referral to Nurse-Led HF Clinic Fup 16 180 Pts (39%) | No Planned Referral to Nurse-Led HF Clinic Fup 24 812 Pts (61%) | P Value |
|------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|---------|
| **Demographics**                               |                                                             |                                                               |         |
| Sex*                                           |                                                             |                                                               |         |
| Male                                           | 11 130 (69%)                                                | 14 762 (60%)                                                  | <0.001  |
| Female                                         | 5050 (31%)                                                  | 10 050 (40%)                                                  |         |
| Age, mean (SD), y*                             | 70 (12)                                                     | 76 (12)                                                       | <0.001  |
| Year of registration*                          |                                                             |                                                               |         |
| 2000–2006                                      | 2233 (14%)                                                  | 5801 (23%)                                                   | <0.001  |
| 2007–2012                                      | 13 947 (86%)                                                | 19 011 (77%)                                                 |         |
| Location when entered in the Swedish HF Registry at baseline* |                                                             |                                                               |         |
| Inpatient                                      | 7379 (46%)                                                  | 15 618 (63%)                                                 | <0.001  |
| Outpatient                                     | 8801 (54%)                                                  | 9194 (37%)                                                   |         |
| Specialty when entered in the Swedish HF Registry at baseline* |                                                             |                                                               |         |
| Cardiology                                     | 8335 (54%)                                                  | 12 799 (55%)                                                 | 0.07    |
| Internal medicine or geriatrics                | 7126 (46%)                                                  | 10 534 (45%)                                                 |         |
| Follow-up referral specialty* (physician specialty; not same as the HF nurse Fup) |                                                             |                                                               |         |
| Primary care or other care                     | 1665 (10%)                                                  | 13 841 (56%)                                                 | <0.001  |
| Cardiology or internal medicine                | 14 246 (90%)                                                | 10 888 (44%)                                                 |         |
| **Clinical**                                   |                                                             |                                                               |         |
| Duration of heart failure, mo*                 |                                                             |                                                               |         |
| <6                                             | 9420 (59%)                                                  | 10 793 (44%)                                                 | <0.001  |
| ≥6                                             | 6643 (41%)                                                  | 13 870 (56%)                                                 |         |
| NYHA*                                          |                                                             |                                                               |         |
| I to II                                        | 7768 (59%)                                                  | 9879 (59%)                                                   | 0.98    |
| III to IV                                      | 5372 (41%)                                                  | 6836 (41%)                                                   |         |
| EF, %*                                         |                                                             |                                                               |         |
| ≥50                                            | 2388 (15%)                                                  | 6958 (28%)                                                   | <0.001  |
| 40 to 49                                       | 3207 (20%)                                                  | 5619 (23%)                                                   |         |
| <40%                                           | 10 585 (65%)                                                | 12 235 (49%)                                                 | <0.001  |
| Body mass index, mean (SD), kg/m²*             | 27.1 (5.4)                                                  | 26.7 (5.5)                                                   | <0.001  |
| **Blood pressure, mean (SD), mm Hg**           |                                                             |                                                               |         |
| Systolic                                       | 126 (21)                                                    | 129 (21)                                                     | <0.001  |
| Diastolic                                      | 74 (12)                                                     | 73 (12)                                                      | 0.005   |
| Mean arterial blood pressure, mean (SD), mm Hg*| 91 (13)                                                     | 92 (13)                                                      | <0.001  |
| Heart rate, mean (SD), bpm*                    | 74 (15)                                                     | 74 (15)                                                      | 0.12    |
| **Laboratory values**                          |                                                             |                                                               |         |
| eGFR, median (IQR), mL/min per 1.73 m²×7       | 65 (49–80)                                                   | 58 (43–74)                                                   | <0.001  |
| Hemoglobin, mean (SD), g/L                     | 135 (17)                                                    | 131 (17)                                                     | <0.001  |
| NT-proBNP, median (IQR), pg/mL*                | 2500 (1112–5740)                                            | 2689 (1132–6161)                                             | 0.001   |

Continued
### Table. Continued

| Variables                              | Planned Referral to Nurse-Led HF Clinic Fup 16 180 Pts (39%) | No Planned Referral to Nurse-Led HF Clinic Fup 24 812 Pts (61%) | P Value |
|----------------------------------------|--------------------------------------------------------------|----------------------------------------------------------------|---------|
| **Concomitant medications**            |                                                              |                                                                |         |
| ACE-I or ARB*                          | 14 808 (92%)                                                | 19 907 (81%)                                                   | <0.001  |
| Mineralocorticoid receptor blockers*   | 4908 (30%)                                                 | 7083 (29%)                                                    | <0.001  |
| Digoxin*                               | 2632 (16%)                                                 | 4433 (18%)                                                    | <0.001  |
| Diuretic*                              | 12 370 (77%)                                               | 20 193 (82%)                                                  | <0.001  |
| Nitrate*                               | 1976 (12%)                                                 | 4795 (19%)                                                    | <0.001  |
| Platelet inhibitor*                    | 7906 (49%)                                                 | 12 846 (52%)                                                  | <0.001  |
| Oral anticoagulant*                    | 6788 (42%)                                                 | 9204 (37%)                                                    | <0.001  |
| Statin*                                | 8051 (50%)                                                 | 10 767 (44%)                                                  | <0.001  |
| Beta-blocker*                          | 14 626 (91%)                                               | 20 842 (84%)                                                  | <0.001  |
| **Device therapy**                     |                                                              |                                                                |         |
| No                                     | 15 301 (95%)                                               | 23 584 (96%)                                                  | <0.001  |
| CRT-P                                  | 190 (1%)                                                   | 320 (1%)                                                      |         |
| CRT-D                                  | 238 (2%)                                                   | 215 (1%)                                                      |         |
| ICD                                    | 339 (2%)                                                   | 413 (2%)                                                      |         |
| **History and comorbidity**            |                                                              |                                                                |         |
| Smoking*                               | 5526 (40%)                                                 | 8472 (46%)                                                    | <0.001  |
| Previous                               | 6160 (45%)                                                 | 7899 (42%)                                                    |         |
| Current                                | 2069 (15%)                                                 | 2230 (12%)                                                    |         |
| Hypertension*                          | 9297 (57%)                                                 | 15 270 (62%)                                                  | <0.001  |
| Diabetes mellitus*                     | 4126 (25%)                                                 | 7016 (28%)                                                    | <0.001  |
| Ischemic heart disease*                | 8198 (53%)                                                 | 13 623 (57%)                                                  | <0.001  |
| Coronary revascularization*            | 5163 (32%)                                                 | 7192 (29%)                                                    | <0.001  |
| Atrial fibrillation/flutter*           | 8307 (51%)                                                 | 14 448 (58%)                                                  | <0.001  |
| Peripheral artery disease*             | 1415 (9%)                                                  | 2671 (11%)                                                    | <0.001  |
| Stroke or transient ischemic attack including intracranial bleed* | 2203 (14%) | 4695 (19%) | <0.001 |
| Severe bleeding*                       | 2857 (18%)                                                 | 5315 (21%)                                                    | <0.001  |
| Valve disease*                         | 3616 (23%)                                                 | 6886 (29%)                                                    | <0.001  |
| Anemia*                                | 4813 (30%)                                                 | 9204 (37%)                                                    | <0.001  |
| Lung disease*                          | 3718 (23%)                                                 | 6635 (27%)                                                    | <0.001  |
| **Socioeconomic variables**            |                                                              |                                                                |         |
| Family type*                           | 7569 (47%)                                                 | 13 356 (54%)                                                  | <0.001  |
| Living alone                           | 8556 (53%)                                                 | 11 426 (46%)                                                  |         |
| Married/cohabitating                   |                                                              |                                                                |         |
| Education*                             | 7248 (45%)                                                 | 12 708 (52%)                                                  | <0.001  |
| Compulsory school                      | 2479 (16%)                                                 | 3261 (13)                                                     |         |
labeled with an asterisk (“*”) in Table as covariates, were run to detect independent predictors of planned referral to a nurse-led HF clinic.

**Prognosis in planned versus non-planned follow-up in a nurse-led HF clinic**

Outcomes of our analysis were time to all-cause death, time to first HF hospitalization (with censoring at death), and time to all-cause death or first HF hospitalization (composite outcome). Unadjusted survivor functions were estimated using the Kaplan–Meier method. Multivariable Cox regression models were fitted in order to calculate the adjusted proportional hazard ratios (HRs) with 95% CIs. They included the same variables as in the logistic regression models as covariates. In order to assess the association between planned follow-up in a nurse-led HF clinic and prognosis in prespecified subgroups of patients, Cox regression models were performed including an interaction term between planned follow-up in a nurse-led HF clinic and relevant variables.

**Sensitivity Analysis**

Given that the time frame considered for this analysis (2000–2012) spanned different periods of HF care (ie, post–renin-angiotensin-system inhibitors and beta-blocker introduction, but before mineralocorticoid receptor antagonists and cardiac resynchronization therapy introduction, and post–mineralocorticoid receptor antagonist and –cardiac resynchronization therapy introduction) and we enrolled also patients with very short follow-up given that both the enrollment and the follow-up ended in 2012, we performed a sensitivity analysis including only patients registered between January 1, 2006 and December 31, 2011.

A value of P<0.05 was considered as statistically significant for all the analyses. Statistical analyses were performed by Stata software (version 14.2; StataCorp LLC, College Station, TX).

**Results**

Between May 11, 2000 and December 31, 2012, 80 772 registrations were recorded from 51 060 unique patients. Of cases, 40 992 patients had no missing data for planned follow-up in a nurse-led HF clinic or EF, or follow-up ≤0 days, and 16 180 (39%) were planned to be followed up in a nurse-led HF clinic.

**Baseline Characteristics**

Baseline characteristics are reported in Table. There were several differences between groups. Patients with planned follow-up in nurse-led HF clinics were more likely male, younger, registered as outpatients in the SwedeHF, followed up in specialty physician care, married or cohabitating, and with higher education and income. They were also more likely to have a shorter HF duration, HF with reduced EF, lower blood pressure and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and higher body mass index, estimated glomerular filtration rate, and hemoglobin levels. Finally, they were less likely to suffer from comorbidities and more likely to receive evidence-based HF therapy.

**Predictors of Planned Referral to a Nurse-Led HF Clinic**

We assessed independent associations of numerous characteristics with planned follow-up in a nurse-led HF clinic. We displayed the adjusted odds ratios in descending order of magnitude in forest plots (Figures 1 and 2).

Among the demographic/organizational variables, follow-up referral in specialist care, being registered in the SwedeHF

### Table. Continued

| Variables                        | Planned Referral to Nurse-Led HF Clinic Fup 16 180 Pts (39%) | No Planned Referral to Nurse-Led HF Clinic Fup 24 812 Pts (61%) | P Value |
|----------------------------------|---------------------------------------------------------------|-----------------------------------------------------------------|---------|
| Income*                          | 6970 (43%)                                                    | 13 445 (54%)                                                   | <0.001  |
| ≤Median                          | 9093 (57%)                                                    | 11 291 (46%)                                                  | 0.41    |
| >Median                          | 2 (1)                                                         | 2 (1)                                                         |         |
| No. of children, mean (SD)*      | 6970 (43%)                                                    | 13 445 (54%)                                                   | <0.001  |
| Variables labeled with an asterisk (“*”) were included in multiple imputation models together with “Planned nurse-led HF clinic follow-up” and the outcome all-cause mortality/HF hospitalization, and in all the multivariable models. Variables were included in the models as reported in Figures 1 and 2 (except for year of registration included as continuous variable). **ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; EF, ejection fraction; eGFR, estimated glomerular filtration rate; Fup, follow-up; HF heart failure; ICD, implantable cardioverter defibrillator; IQR, interquartile range; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association. Calculated by the Modification of Diet in Renal Disease (MDRD) formula. **
as an outpatient, male sex, and being married or cohabitating were associated with planned referral to a nurse-led HF clinic in unadjusted and adjusted analyses, whereas education, age, and income were no longer significant after adjustments. Conversely, in both study arms, patients were more likely to be registered in the SwedeHF in cardiology departments, but after adjustments, those registered in internal medicine/geriatric departments were more likely planned to be referred to nurse-led HF clinics.

Among the clinical/comorbidity variables, HF with reduced EF and HF with mid-range EF subtypes, shorter HF duration, higher NT-proBNP levels, and absence of comorbidities, such as anemia, atrial fibrillation, valvular disease, peripheral artery disease, history of stroke, lung disease, lower blood pressure, and current or previous smoking, were confirmed as independent predictors of planned follow-up in a nurse-led HF clinic after adjustments. In adjusted analyses, higher New York Heart Association (NYHA) class and higher heart rate were also independently associated with likelihood of receiving follow-up in a nurse-led HF clinic. Conversely, other comorbidities, such as body mass index, hypertension, diabetes mellitus, history of severe bleeding, renal function, history of ischemic heart disease, and coronary revascularization, were not independently associated with planned referral to a nurse-led HF clinic after adjustments.

We also investigated the different use of treatments in patients planned to be versus not to be referred to a nurse-led HF clinic. Being prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, and diuretics was

Figure 1. Variables independently associated with planned follow-up in nurse-led heart failure clinic. ACE-I indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter defibrillator; MAP, mean arterial pressure; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York heart association; OR, odds ratio; TIA, transient ischemic attack.
associated with higher likelihood of planned referral, whereas receiving cardiac resynchronization therapy or an implantable cardioverter defibrillator or nitrates was associated with less likelihood of planned referral to a nurse-led HF clinic.

Outcome Analysis

Figure 3A shows the Kaplan–Meier curves for time to all-cause mortality, time to HF hospitalization, and time to all-cause mortality/HF hospitalization in patients planned to be versus not to be referred to a nurse-led HF clinic. In unadjusted analyses, planned follow-up in a nurse-led HF clinic was associated with a significant reduction of risk of all-cause death (HR, 0.61; 95% CI, 0.59–0.63), HF hospitalization (HR, 0.92; 95% CI, 0.89–0.95), and composite of all-cause death and HF hospitalization (HR, 0.77; 95% CI, 0.75–0.79). Median time (interquartile range) to event was 2.2 (0.9–4.1) years for all-cause death and 1.4 (0.4–3.3) years for HF hospitalization/all-cause death. After adjustments, risk of mortality (HR, 0.90; 95% CI, 0.86–0.93) and of the composite outcome (HR, 0.96; 95% CI, 0.93–0.99) remained significantly reduced, whereas risk of HF hospitalization was not significantly associated with planned referral to a nurse-led HF clinic (HR, 1.03; 95% CI, 0.99–1.07).

The association between planned follow-up in a nurse-led HF clinic and outcomes was consistent in most subgroups explored (Figure 4). However, in some of them, such as NYHA class I to II, HF duration <6 months, higher estimated glomerular filtration rate, and absence of concomitant diabetes mellitus and ischemic heart disease, planned referral to a nurse-led HF clinic was associated with even greater benefit in terms of mortality reduction. Planned follow-up in a nurse-led HF clinic was associated with higher risk of HF hospitalization in age ≤75 years, HF with reduced EF and HF with preserved EF, HF duration ≥6 months, and lower NT-proBNP. Risk of the composite outcome was lower in patients planned to be referred to a nurse-led HF clinic with age >75 years, NYHA class I to II, and HF duration <6 months and in patients who did not have diabetes mellitus.

Sensitivity Analysis

Between January 1, 2006 and December 31, 2011, 31 938 patients fulfilled the inclusion/exclusion criteria of our study. Consistently with the main analysis, 38% (12 273 patients) of our population was planned for referral to a nurse-led HF clinic. Distribution of the baseline characteristics of the population considered at the sensitivity analysis was similar to the main analysis (Table S1). After adjustments, planned follow-up in a nurse-led HF clinic was associated with a statistically significant reduction of the risk of all-cause mortality (HR, 0.90; 95% CI, 0.86–0.95) and of the composite outcome (HR, 0.96; 95% CI, 0.93–0.99), but not of HF hospitalization (HR, 1.02; 95% CI, 0.98–1.07; Figure 3B).

Discussion

In this large and comprehensive analysis from the SwedeHF, we observed that patients with more-severe HF were more likely to be planned for referral to nurse-led HF clinics. Indeed, sicker patients may have more need for this type of intervention because of expected poorer prognosis. On the contrary, patients with comorbidities were less likely to be planned for referral to a nurse-led HF clinic, although they had an even larger need for a structured and comprehensive follow-up. We also reported lower likelihood of being referred to a nurse-led HF clinic in patients living alone and women. Our results are concerning given that they show that there is
an unjustified limited referral to this type of follow-up. Indeed, as observed for many other treatments in HF, referral to a nurse-led clinic was limited, although it was associated with reduced mortality.

Utilization of Nurse-Led HF Clinics

In HF, a well-structured follow-up should be provided during the disease trajectory. Indeed, early follow-up during the
vulnerable phase after hospitalization is vital to prevent readmissions and death. Based on American and European HF guidelines, multidisciplinary care is recommended, and a nurse-led HF clinic is 1 established model of this type of care. Despite guidelines recommendations and several meta-analyses that provided evidence of improved survival/
Nurse-Led Heart Failure Clinics and Outcomes  
Savarese et al

DOI: 10.1161/JAHA.118.011737

morbidity,  
implemented in almost all hospitals  
and, to some extent, also in primary care. Nevertheless, we showed that less than half of the population enrolled in our study was planned for referral to a nurse-led HF clinic. Major gains could be made referring patients to this type of follow-up, especially in terms of improving event-free survival, as suggested by our and previous studies.

In Sweden as well as in many other countries worldwide, healthcare legislation provides equal access to care to all citizens. In this report, we found less likelihood of being planned for a follow-up in an HF clinic based on female sex and living alone, which is consistent with previous studies. However, in Sweden, there are no financial or organizational hurdles to implement hospital- and primary-care–based, nurse-led HF clinics, and most patients state that they prefer this type of follow-up. One proposed reason for a lack of structured nurse-led HF referral is that many healthcare providers neglect the importance of monitoring symptoms, optimizing treatment and providing education and psychosocial support to patients with HF. Furthermore, we showed that having comorbidities and suffering from HF with preserved EF/HF with mid-range EF and of less-severe HF (ie, lower NYHA class and NT-proBNP levels and high mean arterial blood pressure) were associated with less likelihood of being planned for referral to HF clinics. A potential explanation for this finding might be that physicians expect more benefit of referral to a nurse-led HF clinic in patients with more-severe HF and less comorbidities. However, this proposed hypothesis is not supported by our data. Indeed, we showed similar benefits in terms of mortality/morbidity in patients with different EF, high versus low NT-proBNP, and lower HR for mortality in those with NYHA I to II and overall reduced risk of outcomes regardless of comorbidities. Additionally, presence of comorbidities in HF is associated with poorer survival and quality of life. As a consequence, a stricter and more-comprehensive follow-up in an HF nurse-led clinic might be even more effective in these patients. Interestingly, we showed that patients registered at baseline in medicine/geriatrics rather than cardiology departments were more likely to be planned for referral, suggesting that referral may have been considered more needed. Patients with planned referral to specialty versus primary-care follow-up care were also more likely to be planned for referral to a nurse-led clinic, suggesting that specialists and HF nurses work in synergy to determine initiation and titration of HF medications and devices during follow-up. There are 2 potential explanations for the association between planned referral to a nurse-led HF clinic and optimized use of HF treatments shown in our analysis. First, patients reported as planned for referral at the index date had been previously referred to an HF nurse-led clinic, which may explain the optimized use of HF therapies. Second, patients who were better treated were also more likely to be planned for referral to nurse-led HF clinic as part of the treatment plan. We also found that patients with HF diagnosed within the past 6 months were more likely to be planned for referral, which may be interpreted by higher expected benefit of intensive HF therapy initiation and titration in the early stages of the condition, as confirmed by our subgroup analysis.

Prognosis Associated With Planned Referral to a Nurse-Led HF Clinic

In previous meta-analyses, follow-up in a nurse-led clinic was associated with improved survival and reduced risk of hospital readmission. However, several individual studies have been inconclusive and have shown inconsistent results. Most trials compared an intervention with “usual care,” but whether usual care in trials published during the early 1990s is comparable to current practice is not clear. Additional issues of published trials were low power, inclusion of highly selected cohort, and use of different control arms, which ranged from intensive follow-up by cardiologists to almost no follow-up at all. Therefore, it is not clear whether previous studies are comparable with current practice and whether their findings may be generalized to real-world setting.

The current analysis, including more than 40 000 patients from the large and unselected HF population of the SwedeHF, showed reduced mortality associated with planned referral to a nurse-led HF clinic, which is consistent with previous evidences. However, similar risk of HF hospitalization was observed in patients who were versus those who were not planned for referral. As previously hypothesized, referral to nurse-led HF clinics could impact on survival by several mechanisms. It could foster treatment optimization and improve patients’ understanding of HF and self-care. It could also promote involvement of other people in patient’s self-care, psychosocial support, and well-being. Finally, it could provide an easier access to health professionals and continuity of care with stricter and longer follow-up.

Referral to HF clinics has been associated with reduced risk of hospitalization in some studies, but not in others and in ours. Inconsistent findings may be explained by differences in content of the interventions, settings, and patient populations. Some hospital admissions may be necessary and beneficial in terms of improving symptoms, health-related quality of life, and survival. Finally, closer monitoring may foster earlier identification of patients with worsening status, who were subsequently hospitalized.
Limitations
Our observational study is subject to confounding and selection bias. Indeed, although we performed extensive adjustments, we cannot rule out potential residual confounding. Exposure in the current analysis was planned referral to a nurse-led HF clinic, so similarly to what happens in trials where treatment is considered according to an intention-to-treat protocol, we cannot exclude that some patients may not have undergone or completed follow-up although suggested at the time of registration in the SwedHF. Notably, each nurse-led HF clinic may vary, based on nurses’ experience, knowledge base in HF, time spent communicating with patients, techniques used in communication (ie, motivational interviewing), teach-back and shared decision making, and, also, based on expectations of physician providers of each practice. Additionally, HF nurse-led clinics may have changed in scope of work over time, as HF therapies advanced. A propensity-matched study design based on temporal trends would consider changes in practice over time and increase comparability between study arms, but limit sample size and generalizability of findings. We do not know the value of nurse-led clinics based on contemporary management; they could be more or less valuable now compared with 2000. Another limitation is the time frame of this report (2000–2012) given that treatments have advanced over time. Our study population was enrolled over 12 years characterized by important changes in HF care (ie, introduction of mineralocorticoid receptor antagonists and cardiac resynchronization therapy). Although we adjusted our analysis for the year of enrollment and baseline therapy, we cannot exclude residual confounding effect of time of enrollment on our findings.

Conclusions
In this nation-wide registry, 39% of our identified HF cohort was planned to be referred to a nurse-led HF clinic. Patients who were planned for referral had more-severe HF, higher use of HF treatments, and less comorbidities at referral. Planned referral was independently associated with lower risk of death, but not of HF hospitalization.

Source of Funding
This study was supported, in part, by grants from the Swedish Research Council (grants 2013-23897-104604-23 and 523-2014-2336) and the Swedish Heart Lung Foundation (grants 20120321 and 20150557). No funding agency had any role in the design and conduct of the study, collection, management, analysis, or interpretation of the data or in the preparation or approval of the manuscript.

Disclosures
Savarese has no conflict of interest related to the current work. Outside the current work, he received research grants from Boehringer Ingelheim and Merck Sharp & Dohme and honoraria from Vifor, Servier, Roche, AstraZeneca, and SPA. Dahlström has no conflict of interest related to the present work. Unrelated to the present work, he received research grants from AstraZeneca and consultancies/honorarias from AstraZeneca and Novartis. Lund has no conflict of interest related to present work. Unrelated to the present work, he received grants and consulting from AstraZeneca, Novartis, and Boehringer Ingelheim, consulting from Sanofi, and consulting from Vifor Pharma. Strömberg has no conflict of interest related to the present work. Unrelated to the present work, she got consultancies/honorarias from Novartis.

References
1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Celanaj D, Chuang A, Cheng S, Chiuve SE, Chuman M, Delling FN, de R, de Ferranti SD, Ferguson JF, Fonseca P, France J, Friesen A, Frighetto L, Gheorghiade M, Gómez-Pariente J, Hall J, Han K, Jankowski JA, Jhund PS, Khot UN, Krum H, Larbalestier D, Lichtman JR, Liew G, Lippey TS, MacIntyre D, MacLean D, Mark M, Masson P, Maudos P, Mebazaa A, Mericq D, Middeldorp S, Mulligan J, Nolte IM, Opie L, Parissis JT, Pieske B, Riley JP, Rosano GM, Rutten LJ, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
3. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gilliespie C, Issac CR, Jimenez MC, Jordan LC, Judd SE, Lackl D, Lichtman JH, Liaseth B, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, OFlaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves M, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voes JH, Wilkins JF, Wilkins JT, Wu JH, Alper HM, Wong SS, Munter P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
4. Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–e327.
5. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. 2015;12:220–229.
6. Lijeroos M, Stromberg A. Introducing nurse-led heart failure clinics in Swedish primary care settings. Eur J Heart Fail. 2019;21:103–109.
7. Stromberg A, Martensson J, Fridlund B, Dahlstrom U. Nurse-led heart failure clinics in Sweden. Eur J Heart Fail. 2001;3:139–144.
8. Riley JP, Astin F, Crespo-Leiro MG, Deaton CM, Kienhorst J, Lambiriniou E, McDonagh TA, Rushton CA, Stromberg A, Filippatos G, Anker SD. Heart failure association of the European Society of Cardiology Heart Failure Nurse Curriculum. Eur J Heart Fail. 2016;18:736–743.
9. Van Spall HGC, Rahman T, Mytton O, Ramsundarahettige C, Ibrahim Q, Kazali C, Coopmans M, Brian Haynes R, Connolly S. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail. 2017;19:1427–1443.
10. Feltner C, Jones CD, Cene CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ, Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care interventions
to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med. 2014;160:774–784.

11. Gandhi S, Mosleh W, Sharma UC, Demers C, Farkouh ME, Schwalm JD. Multidisciplinary heart failure clinics are associated with lower heart failure hospitalization and mortality: systematic review and meta-analysis. Can J Cardiol. 2017;33:1237–1244.

12. Jonsson A, Edner M, Alehagen U, Dahlstrom U. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12:25–31.

13. Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, Lund LH. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11,215 patients from the Swedish heart failure registry. Eur J Heart Fail. 2018;20:1326–1334.

14. Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. Association between demographic, organizational, clinical, and socioeconomic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail. 2017;19:1270–1279.

15. Jonkman NH, Westland H, Groenwold RH, Agren S, Atienza F, Blue L, Bruggink-Andre de la Porte PW, DeWalt DA, Hebert PL, Heisler M, Jaarsma T, Kempfen GI, Leventhal ME, Lok DJ, Martensson J, Muniz J, Otsu H, Peters-Klimm F, Rich MW, Riegel B, Stromberg A, van Veldhuisen DJ, Trappenburg JC, Schuurmans MJ, Hoes AW. Do self-management interventions work in patients with heart failure? An individual patient data meta-analysis. Circulation. 2016;133:1189–1198.

16. Seferovic PM, Stoerk S, Filippatos G, Mareev V, Kavolluniene A, Ristic AD, Ponikowski P, McMurray J, Maggioni A, Ruschitzka F, van Veldhuisen DJ, Coats A, Piepoli M, McDonagh T, Riley J, Hoes A, Pieles B, Dobric M, Papp Z, Meebaza A, Parissis J, Ben Gal T, Vinereanu D, Brito D, Altenberger J, Gatzov P, Milinkovic I, Hradec J, Trochu JN, Amir O, Moura B, Lainsez M, Comin J, Wikstrom G, Anker S; Committee of National Heart Failure Societies or Working Groups of the Heart Failure Association of the European Society of Cardiology, Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in Collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail. 2013;15:947–959.

17. Stromberg A, Martensson J, Fridlund B, Levin LA, Karlsson JE, Dahlstrom U. Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial. Eur Heart J. 2003;24:1014–1023.

18. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet. 1999;354:1077–1083.

19. Lundberg O. The next step towards more equity in health in Sweden: how can we close the gap in a generation? Scand J Public Health. 2018;46:19–27.

20. United Nations. The sustainable development agenda. Available at: https://www.un.org/sustainabledevelopment/development-agenda/. Accessed May 9, 2019.

21. Savarese G, Sartipy U, Friberg L, Dahlstrom U, Lund LH. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. Heart. 2018;104:1093–1100.

22. Jaarsma T, Stromberg A. Heart failure clinics are still useful (more than ever?). Can J Cardiol. 2014;30:272–275.

23. Lawson CA, Dolis-Trapala I, Dahlstrom U, Mamas M, Jaarsma T, Kadam UT, Stromberg A. Comorbidity health pathways in heart failure patients: a sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish heart failure registry. PLoS Med. 2018;15:e1002540.

24. Ansari M, Alexander M, Tutar A, Bello D, Massie BM. Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. J Am Coll Cardiol. 2003;41:62–68.

25. Jaarsma T, van der Wal MH, Lesman-Leegte I, Lutik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, van Veldhuisen DJ. Effect of moderate or intensive disease management program on outcome in patients with heart failure: coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168:316–324.

26. Angermann CE, Stork S, Gelbrich G, Faller J, Jahns R, Frantzi S, Loef M. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail. 2012;5:25–35.

27. Jonkman NH, Westland H, Groenwold RH, Agren S, Anguita M, Blue L, Bruggink-Andre de la Porte PW, DeWalt DA, Hebert PL, Heisler M, Jaarsma T, Kempfen GI, Leventhal ME, Lok DJ, Martensson J, Muniz J, Otsu H, Peters-Klimm F, Rich MW, Riegel B, Stromberg A, Trappenburg JC, Schuurmans MJ, Hoes AW. What are effective program characteristics of self-management interventions in patients with heart failure? An individual patient data meta-analysis. J Card Fail. 2016;22:861–871.

28. Clark AM, Wiens KS, Banner D, Kryworuchko J, Thirsk L, McLean L, Currie K. A systematic review of the main mechanisms of heart failure disease management interventions. Heart. 2016;102:707–711.

29. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–1195.
Table S1. Baseline characteristics in patients enrolled between 2006 and 2011 (sensitivity analysis).

| Variables                                           | No planned referral to nurse-led HF clinic fup | Planned referral to nurse-led HF clinic fup | p     |
|-----------------------------------------------------|-----------------------------------------------|--------------------------------------------|-------|
|                                                     | 19,665 pts (38%)                              | 12,273 pts (62%)                           |       |
| Sex                                                 |                                               |                                            | <0.001|
| Male                                                | 11708 (59.5%)                                 | 8452 (68.9%)                               |       |
| Female                                              | 7957 (40.5%)                                  | 3821 (31.1%)                               |       |
| Age, mean (SD), y                                   | 76 (12)                                       | 70 (12)                                    | <0.001|
| Location when entered in the Swedish HF Registry at baseline |                                               |                                            |       |
| Inpatient                                           | 12448 (63.3%)                                 | 5575 (45.4%)                               | <0.001|
| Outpatient                                          | 7217 (36.7%)                                  | 6698 (54.6%)                               |       |
| Specialty when entered in the Swedish HF Registry at baseline |                                               |                                            |       |
| Internal medicine/Geriatrics                        | 7864 (43.3%)                                  | 5498 (47.0%)                               | <0.001|
| Cardiology                                          | 10315 (56.7%)                                 | 6189 (53.0%)                               |       |
| Follow-up referral specialty (physician specialty; not same as the HF nurse FUP) |                                               |                                            |       |
| Cardiology or Internal medicine                     | 8500 (43.3%)                                  | 10751 (89.5%)                              | <0.001|
| Primary care or Other care                          | 11108 (56.7%)                                 | 1258 (10.5%)                               |       |
| Duration of heart failure, months                   |                                               |                                            |       |
| <6                                                  | 8417 (43.0%)                                  | 7010 (57.5%)                               | <0.001|
| >6                                                  | 11136 (57.0%)                                 | 5189 (42.5%)                               |       |
| NYHA                                                |                                               |                                            |       |
| I-II                                                | 7817 (59.2%)                                  | 5983 (59.2%)                               | 0.99  |
| III-IV                                              | 5384 (40.8%)                                  | 4122 (40.8%)                               |       |
| EF, %                                               |                                               |                                            |       |
| >50                                                 | 5574 (28.3%)                                  | 1797 (14.6%)                               | <0.001|
| 40-49                                               | 4463 (22.7%)                                  | 2484 (20.2%)                               |       |
| <30                                                 | 9628 (49.0%)                                  | 7992 (65.2%)                               |       |
| Body mass index, mean (SD), kg/m2                   | 27 (6)                                        | 27 (5)                                     | <0.001|
| Blood pressure, mean (SD), mmHg                     |                                               |                                            |       |
| Systolic                                            | 129 (21)                                      | 126 (21)                                   | <0.001|
| Diastolic                                           | 73 (12)                                       | 73 (12)                                    | 0.062 |
| Mean arterial blood pressure, mean (SD), mmHg       |                                               |                                            |       |
|                                                     | 92 (13)                                       | 91 (13)                                    | <0.001|
| Heart Rate, mean (SD), beats/min                    | 74 (15)                                       | 74 (15)                                    | 0.033 |
| eGFR, median (IQR), ml/min/1.73m2                   | 58 (43, 74)                                   | 64 (49, 80)                                | <0.001|
| Hemoglobin, mean (SD), g/L                          | 131 (17)                                      | 135 (17)                                   | <0.001|
| Variable                                           | Value 1       | Value 2       | P-value  |
|----------------------------------------------------|---------------|---------------|----------|
| NT-proBNP, median (IQR), pg/mL                     | 2640 (1110, 6140) | 2513 (1131, 5468) | 0.053    |
| ACE-I or ARB                                      | 15848 (81.1%) | 11248 (91.8%) | <0.001   |
| Mineralocorticoid receptor blockers               | 5532 (28.3%)  | 3634 (29.7%)  | 0.007    |
| Digoxin                                            | 3405 (17.4%)  | 2021 (16.5%)  | 0.038    |
| Diuretic                                           | 15887 (81.1%) | 9342 (76.4%)  | <0.001   |
| Nitrate                                            | 3785 (19.4%)  | 1504 (12.3%)  | <0.001   |
| Platelet inhibitor                                 | 10259 (52.5%) | 6124 (50.1%)  | <0.001   |
| Oral anticoagulant                                 | 7226 (37.0%)  | 5063 (41.4%)  | <0.001   |
| Statin                                             | 8781 (44.9%)  | 6226 (50.9%)  | <0.001   |
| Beta-Blocker                                       | 16501 (84.3%) | 11099 (90.6%) | <0.001   |
| Device therapy                                     | <0.001        |               |          |
| CRT-P                                              | 296 (1.5%)    | 174 (1.4%)    |          |
| CRT-D                                              | 188 (1.0%)    | 172 (1.4%)    |          |
| ICD                                                | 339 (1.7%)    | 253 (2.1%)    |          |
| Smoking                                            |               |               |          |
| Never                                              | 6612 (45.1%)  | 4213 (40.4%)  | <0.001   |
| Previous                                           | 6276 (42.8%)  | 4689 (45.0%)  |          |
| Current                                            | 1769 (12.1%)  | 1529 (14.7%)  |          |
| Hypertension                                       | 12270 (62.4%) | 7081 (37.7%)  | <0.001   |
| Diabetes                                           | 5600 (28.5%)  | 3121 (25.4%)  | <0.001   |
| Ischemic heart disease                             | 10830 (56.6%) | 6350 (53.8%)  | <0.001   |
| Coronary revascularization                         | 5803 (29.5%)  | 4018 (32.7%)  | <0.001   |
| Atrial fibrillation/flutter                        | 11511 (58.5%) | 6318 (51.5%)  | <0.001   |
| Peripheral artery disease                          | 2168 (11.0%)  | 1072 (8.7%)   | <0.001   |
| Stroke or transient ischemic attack incl intracranial bleed | 3733 (19.0%)  | 1664 (13.6%)  | <0.001   |
| Severe bleeding                                    | 4384 (22.3%)  | 2180 (17.8%)  | <0.001   |
| Valve disease                                      | 5414 (28.1%)  | 2762 (22.8%)  | <0.001   |
| Anemia                                             | 7407 (37.7%)  | 3649 (29.7%)  | <0.001   |
| Lung disease                                       | 5378 (27.3%)  | 2820 (23.0%)  | <0.001   |
| Family type                                        |               |               |          |
| Living alone                                       | 10622 (54.1%) | 5708 (46.7%)  | <0.001   |
| Married/cohabitating                               | 9019 (45.9%)  | 6521 (53.3%)  |          |
| Education                                          |               |               |          |
| Compulsory school                                  | 9977 (51.4%)  | 5528 (45.6%)  | <0.001   |
| Secondary school                                   | 6847 (35.3%)  | 4753 (39.2%)  |          |
| University                                         | 2580 (13.3%)  | 1843 (15.2%)  |          |
| Income                                             |               |               |          |
| < median                                           | 9099 (46.4%)  | 6854 (56.3%)  | <0.001   |
| > median                                           | 10506 (53.6%) | 5325 (43.7%)  |          |
| Number of children, mean (SD)*                     | 2 (1)         | 2 (1)         | 0.50     |